

Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Rx Data Presented at 1st European Congress of Hereditary ATTR Amyloidosis and Provide Phase 3 Development Plan Update

October 27, 2015

- Webcast scheduled on Tuesday, November 3 at 8:00 a.m. Eastern Time

CARLSBAD, Calif., Oct. 27, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Tuesday, November 3 at 8:00 a.m. Eastern Time to review ISIS-TTR_{Rx} data presented at the 1st European Congress of Hereditary ATTR Amyloidosis and provide Phase 3 development plan update.



Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.isispharm.com. A webcast replay will be available for a limited time at the same address.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Isis has created a large pipeline of first-in-class or best-in-class drugs, with over a dozen drugs in mid- to late-stage development. Drugs currently in Phase 3 development include volanesorsen, a drug Isis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with familial chylomicronemia syndrome and familial partial lipodystrophy; ISIS-TTR_{Rx}, a drug Isis is developing with GSK to treat patients with all forms of TTR amyloidosis; and ISIS-SMN_{Rx}, a drug Isis is developing with Biogen to treat infants and children with spinal muscular atrophy. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis Pharmaceuticals' financial position and outlook, Isis' business, and the therapeutic and commercial potential of Isis' technologies and products in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2014, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Isis Pharmaceuticals, Inc. KYNAMRO® is a registered trademark of Genzyme Corporation.

Logo - <http://photos.prnewswire.com/prnh/20130807/LA600061LOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/isis-pharmaceuticals-to-host-webcast-to-review-isis-ttr-rx-data-presented-at-1st-european-congress-of-hereditary-attr-amyloidosis-and-provide-phase-3-development-plan-update-300166397.html>

SOURCE Isis Pharmaceuticals, Inc.

D. Wade Walke, Ph.D., Vice President, Corporate Communications and Investor Relations, 760-603-2741, Amy Williford, Ph.D., Associate Director, Corporate Communications, 760-603-2772